News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,892 Results
Type
Article (44281)
Company Profile (328)
Press Release (670283)
Multimedia
Podcasts (78)
Webinars (12)
Section
Business (207882)
Career Advice (2024)
Deals (35947)
Drug Delivery (109)
Drug Development (83978)
Employer Resources (174)
FDA (16662)
Job Trends (15107)
News (352604)
Policy (33257)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (6)
2024 BioForest Standard (1)
2024 BioMidwest Digital (10)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (11)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (10)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2684)
Academic (1)
Accelerated approval (6)
Adcomms (26)
Allergies (84)
Alliances (50741)
ALS (90)
Alzheimer's disease (1428)
Antibody-drug conjugate (ADC) (131)
Approvals (16642)
Artificial intelligence (251)
Autoimmune disease (23)
Automation (14)
Bankruptcy (365)
Best Places to Work (11853)
BIOSECURE Act (21)
Biosimilars (107)
Biotechnology (237)
Bladder cancer (67)
Brain cancer (30)
Breast cancer (273)
Cancer (2167)
Cardiovascular disease (179)
Career advice (1689)
Career pathing (29)
CAR-T (163)
Cell therapy (454)
Cervical cancer (20)
Clinical research (67998)
Collaboration (837)
Compensation (503)
Complete response letters (27)
COVID-19 (2664)
CRISPR (44)
C-suite (233)
Cystic fibrosis (105)
Data (2062)
Decentralized trials (2)
Denatured (22)
Depression (46)
Diabetes (268)
Diagnostics (6471)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (104)
Drug shortages (28)
Duchenne muscular dystrophy (95)
Earnings (87176)
Editorial (38)
Employer branding (21)
Employer resources (148)
Events (114810)
Executive appointments (686)
FDA (17837)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (738)
Gene editing (110)
Generative AI (21)
Gene therapy (330)
GLP-1 (758)
Government (4514)
Grass and pollen (4)
Guidances (50)
Healthcare (19322)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (120)
Indications (27)
Infectious disease (2804)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (92)
Interviews (313)
IPO (16731)
IRA (42)
Job creations (3693)
Job search strategy (1434)
Kidney cancer (10)
Labor market (35)
Layoffs (490)
Leadership (17)
Legal (8008)
Liver cancer (75)
Lung cancer (315)
Lymphoma (141)
Machine learning (4)
Management (58)
Manufacturing (294)
MASH (67)
Medical device (13575)
Medtech (13580)
Mergers & acquisitions (19721)
Metabolic disorders (700)
Multiple sclerosis (73)
NASH (18)
Neurodegenerative disease (99)
Neuropsychiatric disorders (29)
Neuroscience (1959)
NextGen: Class of 2025 (6720)
Non-profit (4577)
Northern California (2528)
Now hiring (37)
Obesity (376)
Opinion (219)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (80)
Parkinson's disease (151)
Partnered (20)
Patents (221)
Patient recruitment (102)
Peanut (48)
People (58243)
Pharmaceutical (76)
Pharmacy benefit managers (18)
Phase I (21221)
Phase II (29895)
Phase III (22333)
Pipeline (1122)
Policy (131)
Postmarket research (2721)
Preclinical (9000)
Press Release (69)
Prostate cancer (101)
Psychedelics (38)
Radiopharmaceuticals (261)
Rare diseases (402)
Real estate (6012)
Recruiting (67)
Regulatory (22801)
Reports (46)
Research institute (2429)
Resumes & cover letters (352)
Rett syndrome (4)
RNA editing (4)
RSV (40)
Schizophrenia (71)
Series A (131)
Series B (83)
Service/supplier (12)
Sickle cell disease (56)
Southern California (2179)
Special edition (17)
Spinal muscular atrophy (155)
Sponsored (29)
Startups (3707)
State (2)
Stomach cancer (16)
Supply chain (62)
Tariffs (17)
The Weekly (54)
United States (22227)
Vaccines (694)
Venture capitalists (37)
Weight loss (260)
Women's health (36)
Worklife (16)
Date
Today (58)
Last 7 days (477)
Last 30 days (2525)
Last 365 days (34109)
2025 (9051)
2024 (36310)
2023 (41054)
2022 (52299)
2021 (56828)
2020 (55099)
2019 (47636)
2018 (35958)
2017 (33040)
2016 (32445)
2015 (38453)
2014 (32166)
2013 (27179)
2012 (29335)
2011 (30046)
2010 (28197)
Location
Africa (746)
Alabama (51)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (39109)
Australia (6481)
California (5787)
Canada (1925)
China (507)
Colorado (257)
Connecticut (268)
Delaware (134)
Europe (86036)
Florida (867)
Georgia (206)
Idaho (58)
Illinois (522)
India (25)
Indiana (302)
Iowa (9)
Japan (150)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (863)
Massachusetts (4421)
Michigan (213)
Minnesota (380)
Mississippi (2)
Missouri (85)
Montana (28)
Nebraska (25)
Nevada (57)
New Hampshire (67)
New Jersey (1656)
New Mexico (30)
New York (1654)
North Carolina (1000)
North Dakota (8)
Northern California (2528)
Ohio (197)
Oklahoma (15)
Oregon (34)
Pennsylvania (1305)
Puerto Rico (10)
Rhode Island (29)
South America (1120)
South Carolina (18)
South Dakota (1)
Southern California (2179)
Tennessee (98)
Texas (860)
Utah (172)
Virginia (136)
Washington D.C. (62)
Washington State (535)
West Virginia (3)
Wisconsin (51)
714,892 Results for "chimeric therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
The Chimeric Antigen Receptor (CAR) T-Cell Therapy markets to reach US$ 12,482.2 Million by 2035, exhibiting, Impelled by Technological Advancements in CAR-T Therapy
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook 2025-2035:
February 17, 2025
·
13 min read
Press Releases
Research by City of Hope and Other Scientists May Help Patients Overcome Resistance to Chimeric Antigen Receptor (CAR) T Cell Therapy
December 24, 2024
·
5 min read
Press Releases
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
October 23, 2024
·
3 min read
Press Releases
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
April 2, 2025
·
10 min read
Mergers & acquisitions
AstraZeneca Makes Potential $1B Cell Therapy Play in EsoBiotec Buy
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.
March 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
March 27, 2025
·
8 min read
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric’s first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
October 31, 2023
·
4 min read
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.
March 31, 2025
·
5 min read
·
BioSpace Insights
Biotech Bay
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.
June 10, 2024
·
5 min read
Press Releases
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
March 6, 2025
·
4 min read
1 of 71,490
Next
